Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic γδ T cells + targeted therapy + PD-1 monoclonal antibody
- Development stage
- Unknown
- Lead developer
- Beijing GD Initiative Cell Therapy
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cell Therapies, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy regimen is being developed and evaluated by Beijing 302 Hospital (the Fifth Medical Center of the PLA General Hospital) for the first-line treatment of BCLC stage B or C hepatocellular carcinoma (HCC). The protocol integrates three distinct therapeutic modalities: adoptively transferred allogeneic γδ T cells, which are ex-vivo expanded from healthy donors to provide innate-like anti-tumor activity; targeted tyrosine kinase inhibitors (TKIs) such as lenvatinib or sorafenib, which inhibit multiple receptors including VEGFR1-3, FGFR1, PDGFR, c-Kit, and Ret to disrupt tumor angiogenesis and proliferation; and a PD-1 monoclonal antibody, which acts as an immune checkpoint inhibitor to restore the activity of cytotoxic T lymphocytes. This synergistic approach is currently being investigated in a Phase I clinical trial to assess its safety and efficacy in patients with advanced liver cancer.
- Other names
- targeted drugs-Beijing 302 Hospital-hepatocellular carcinomaAllogeneic γδ T Cells with Targeted Therapy and PD-1 mAb in HCCγδ T cells + Targeted drugs + PD-1 monoclonal antibody
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFR (PDGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on allogeneic γδ T cells + targeted therapy + PD-1 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic γδ T cells + targeted therapy + PD-1 monoclonal antibody.